Cosmo First Q1 FY27: Sales Soar 46%, EBITDA Climbs 26%

Cosmo First's consolidated sales for the June 2026 quarter (Q1 FY27) surged by 46% year-on-year to Rs 1,166 crore. EBITDA for the period rose 26% to Rs 147 crore.

Reader Takeaway: Strong revenue growth driven by specialty products and new ventures, but margin pressure and debt reduction remain key watch points.

What just happened

Cosmo First announced its Q1 FY27 financial results, showcasing significant top-line growth. Consolidated sales reached Rs 1,166 crore, a 46% increase compared to the same quarter last year. EBITDA saw a 26% rise to Rs 147 crore.

However, the EBITDA margin dipped to 12.6% from 14.5% YoY. This was partly due to passing on higher raw material costs to customers, which inflated the revenue figure, and also impacted by lower export volumes due to port congestion.

Why this matters

The robust sales growth indicates strong demand for Cosmo First's products, particularly from its specialty film business and expanding rigid packaging and specialty chemical segments. The reported EBITDA increase, despite margin pressure, signals operational improvements. The company's focus on deleveraging and improving Return on Capital Employed (ROCE) is crucial for long-term shareholder value.

The backstory

Cosmo First has recently completed a major capex cycle of Rs 1,200 crore over the last three years. The company has been strategically diversifying and increasing its specialty product mix, which currently stands at 61% for films. Its subsidiaries in specialty chemicals and rigid packaging are also showing strong growth.

What changes now

The company is shifting its focus towards capital efficiency and debt reduction. The management aims to bring down the net debt to EBITDA ratio to below 2x within 12 months and reduce total net debt by Rs 400-500 crore in two years. The target is to achieve a ROCE of 15%-20% in the next 12-24 months.

Risks to watch

Concerns include inventory gains contributing to margin performance, the longer-than-expected breakeven timeline for the Zigly petcare business (estimated two years), and external factors like port congestion impacting exports and foreign currency fluctuations affecting other income.

Peer comparison

While specific peer comparisons were not detailed in the filing, the company's focus on increasing specialty product mix in films and growing its specialty chemical and packaging verticals aligns with broader industry trends towards higher-margin, value-added products.

Context metrics (time-bound)

• Consolidated Sales: Rs 1,166 crore (Q1 FY27), up 46% YoY.
• EBITDA: Rs 147 crore (Q1 FY27), up 26% YoY.
• EBITDA Margin: 12.6% (Q1 FY27), down from 14.5% YoY.
• Specialty Film Mix: 61%.
• Net Debt: Rs 1,166 crore (flat YoY), at 2.3x EBITDA.
• FY27 Guidance: 20% overall topline growth expected.

What to track next

Investors will be watching the company's progress on its debt reduction targets, its ability to improve ROCE to the guided 15-20% range, and the growth trajectory of its newer business segments, particularly specialty chemicals and consumer ventures.